Compare AKBA & CLDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AKBA | CLDT |
|---|---|---|
| Founded | 2007 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 380.4M | 362.9M |
| IPO Year | 2014 | N/A |
| Metric | AKBA | CLDT |
|---|---|---|
| Price | $1.42 | $8.32 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | $5.25 | ★ $9.50 |
| AVG Volume (30 Days) | ★ 2.3M | 210.8K |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 4.46% |
| EPS Growth | ★ 93.94 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $1.29 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $610.21 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.14 | $6.08 |
| 52 Week High | $4.08 | $8.45 |
| Indicator | AKBA | CLDT |
|---|---|---|
| Relative Strength Index (RSI) | 54.02 | 66.02 |
| Support Level | $1.30 | $6.88 |
| Resistance Level | $1.55 | $8.45 |
| Average True Range (ATR) | 0.06 | 0.22 |
| MACD | -0.00 | 0.03 |
| Stochastic Oscillator | 67.65 | 88.24 |
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.
Chatham Lodging Trust is a U.S.-based real estate investment trust that invests in upscale extended-stay hotels. The firm operates across various states in the U.S., including California, New York, Texas, Florida, Minnesota, Massachusetts, and Pennsylvania among others. Substantially all of the company's assets are held and operated by its Operating Partnership, Chatham Lodging, LP. Chatham Lodging LP and its subsidiaries lease the overall company's hotels. The firm operates through a single segment because of the similar economic characteristics of its hotels. Chatham's revenue streams include Room, Food and beverage, and Other. Room comprises the majority of total revenue. Chatham's hotels operate under brands which include, Hilton, Marriott, and Hyatt.